Use of Amniostat-FLM in detecting the presence of phosphatidylglycerol in vaginal pool samples in preterm premature rupture of membranes

David F. Lewis, Craig Towers, Carol A. Major, Tamerou Asrat, Michael P. Nageotte, Roger K. Freeman, Thomas J. Garite

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE: The presence of phosphatidylglycerol in amniotic fluid from the vaginal pool has been established as a reliable marker of pulmonary maturity in pregnancies complicated by preterm premature rupture of membranes because its presence is not affected by contaminants. This study was undertaken to determine the distribution of positive phosphatidylglycerol relative to gestational age from vaginal pool amniotic fluid samples and to assess the efficacy and accuracy of the Amniostat-FLM (liana Biologics; Irvine Scientific after Sept. 14, 1989), an antibody agglutination method for rapidly detecting phosphatidylglycerol. STUDY DESIGN: All singleton nondiabetic pregnancies between 26 and 36 weeks with premature rupture of membranes from whom a vaginal pool sample was obtained were studied. The percent positive by gestational age was analyzed. The neonates that were delivered with a positive phosphatidylglycerol were evaluated for the presence of hyaline membrane disease and other immediate sequelae of prematurity. RESULTS: Of the 201 vaginal pool amniotic fluid samples assayed for phosphatidylglycerol with the Amniostat-FLM procedure, 18% (36/201) were positive for phosphatidylglycerol and none of the delivered infants developed hyaline membrane disease. CONCLUSION: The Amniostat-FLM seems to be accurate in predicting pulmonary maturity from vaginal pool samples.

Original languageEnglish (US)
Pages (from-to)573-576
Number of pages4
JournalAmerican Journal of Obstetrics and Gynecology
Volume169
Issue number3
DOIs
StatePublished - Jan 1 1993

Fingerprint

Phosphatidylglycerols
Amniotic Fluid
Hyaline Membrane Disease
Gestational Age
Pregnancy
Lung
Agglutination
Biological Products
Preterm Premature Rupture of the Membranes
Rupture
Newborn Infant
Membranes
Antibodies

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Use of Amniostat-FLM in detecting the presence of phosphatidylglycerol in vaginal pool samples in preterm premature rupture of membranes. / Lewis, David F.; Towers, Craig; Major, Carol A.; Asrat, Tamerou; Nageotte, Michael P.; Freeman, Roger K.; Garite, Thomas J.

In: American Journal of Obstetrics and Gynecology, Vol. 169, No. 3, 01.01.1993, p. 573-576.

Research output: Contribution to journalArticle

Lewis, David F. ; Towers, Craig ; Major, Carol A. ; Asrat, Tamerou ; Nageotte, Michael P. ; Freeman, Roger K. ; Garite, Thomas J. / Use of Amniostat-FLM in detecting the presence of phosphatidylglycerol in vaginal pool samples in preterm premature rupture of membranes. In: American Journal of Obstetrics and Gynecology. 1993 ; Vol. 169, No. 3. pp. 573-576.
@article{9fa270e8c1174442bba575359a1439d1,
title = "Use of Amniostat-FLM in detecting the presence of phosphatidylglycerol in vaginal pool samples in preterm premature rupture of membranes",
abstract = "OBJECTIVE: The presence of phosphatidylglycerol in amniotic fluid from the vaginal pool has been established as a reliable marker of pulmonary maturity in pregnancies complicated by preterm premature rupture of membranes because its presence is not affected by contaminants. This study was undertaken to determine the distribution of positive phosphatidylglycerol relative to gestational age from vaginal pool amniotic fluid samples and to assess the efficacy and accuracy of the Amniostat-FLM (liana Biologics; Irvine Scientific after Sept. 14, 1989), an antibody agglutination method for rapidly detecting phosphatidylglycerol. STUDY DESIGN: All singleton nondiabetic pregnancies between 26 and 36 weeks with premature rupture of membranes from whom a vaginal pool sample was obtained were studied. The percent positive by gestational age was analyzed. The neonates that were delivered with a positive phosphatidylglycerol were evaluated for the presence of hyaline membrane disease and other immediate sequelae of prematurity. RESULTS: Of the 201 vaginal pool amniotic fluid samples assayed for phosphatidylglycerol with the Amniostat-FLM procedure, 18{\%} (36/201) were positive for phosphatidylglycerol and none of the delivered infants developed hyaline membrane disease. CONCLUSION: The Amniostat-FLM seems to be accurate in predicting pulmonary maturity from vaginal pool samples.",
author = "Lewis, {David F.} and Craig Towers and Major, {Carol A.} and Tamerou Asrat and Nageotte, {Michael P.} and Freeman, {Roger K.} and Garite, {Thomas J.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1016/0002-9378(93)90624-R",
language = "English (US)",
volume = "169",
pages = "573--576",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Use of Amniostat-FLM in detecting the presence of phosphatidylglycerol in vaginal pool samples in preterm premature rupture of membranes

AU - Lewis, David F.

AU - Towers, Craig

AU - Major, Carol A.

AU - Asrat, Tamerou

AU - Nageotte, Michael P.

AU - Freeman, Roger K.

AU - Garite, Thomas J.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - OBJECTIVE: The presence of phosphatidylglycerol in amniotic fluid from the vaginal pool has been established as a reliable marker of pulmonary maturity in pregnancies complicated by preterm premature rupture of membranes because its presence is not affected by contaminants. This study was undertaken to determine the distribution of positive phosphatidylglycerol relative to gestational age from vaginal pool amniotic fluid samples and to assess the efficacy and accuracy of the Amniostat-FLM (liana Biologics; Irvine Scientific after Sept. 14, 1989), an antibody agglutination method for rapidly detecting phosphatidylglycerol. STUDY DESIGN: All singleton nondiabetic pregnancies between 26 and 36 weeks with premature rupture of membranes from whom a vaginal pool sample was obtained were studied. The percent positive by gestational age was analyzed. The neonates that were delivered with a positive phosphatidylglycerol were evaluated for the presence of hyaline membrane disease and other immediate sequelae of prematurity. RESULTS: Of the 201 vaginal pool amniotic fluid samples assayed for phosphatidylglycerol with the Amniostat-FLM procedure, 18% (36/201) were positive for phosphatidylglycerol and none of the delivered infants developed hyaline membrane disease. CONCLUSION: The Amniostat-FLM seems to be accurate in predicting pulmonary maturity from vaginal pool samples.

AB - OBJECTIVE: The presence of phosphatidylglycerol in amniotic fluid from the vaginal pool has been established as a reliable marker of pulmonary maturity in pregnancies complicated by preterm premature rupture of membranes because its presence is not affected by contaminants. This study was undertaken to determine the distribution of positive phosphatidylglycerol relative to gestational age from vaginal pool amniotic fluid samples and to assess the efficacy and accuracy of the Amniostat-FLM (liana Biologics; Irvine Scientific after Sept. 14, 1989), an antibody agglutination method for rapidly detecting phosphatidylglycerol. STUDY DESIGN: All singleton nondiabetic pregnancies between 26 and 36 weeks with premature rupture of membranes from whom a vaginal pool sample was obtained were studied. The percent positive by gestational age was analyzed. The neonates that were delivered with a positive phosphatidylglycerol were evaluated for the presence of hyaline membrane disease and other immediate sequelae of prematurity. RESULTS: Of the 201 vaginal pool amniotic fluid samples assayed for phosphatidylglycerol with the Amniostat-FLM procedure, 18% (36/201) were positive for phosphatidylglycerol and none of the delivered infants developed hyaline membrane disease. CONCLUSION: The Amniostat-FLM seems to be accurate in predicting pulmonary maturity from vaginal pool samples.

UR - http://www.scopus.com/inward/record.url?scp=0027433517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027433517&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(93)90624-R

DO - 10.1016/0002-9378(93)90624-R

M3 - Article

VL - 169

SP - 573

EP - 576

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -